News – Page 1176 – Endpoints News

Evotec signs up for a 5-year discovery deal with Bayer focused on chronic kidney disease

9 years ago

Genentech dives into mRNA, betting $310M on BioNTech's personalized cancer vaccine tech

9 years ago

Mast’s sickle cell drug flunks PhIII, eclipsing shares

9 years ago

Allergan goes on a buying spree for NASH drugs, adding Akarna in M&A double header

9 years ago

Alnylam will hire 100 for its new UK office; Puma shares surge as FDA accepts neratinib NDA

9 years ago

Pridopidine is still a mess in latest Huntington’s study, but Teva maps PhIII

9 years ago

Say what? Allergan just agreed to pay a 6X cash premium for Tobira and its troubled PhIII NASH drug

9 years ago

Teva inks $2.6B deal to buy into Regeneron’s PhIII NGF pain drug

9 years ago

GSK makes a little history while outlining a familiar future

9 years ago

Shire wants out of that $172M Baxalta deal with CTI Bio

9 years ago

Senior FDA officials warned that approving $300,000 Duchenne drug will lower agency standards

9 years ago

GE blueprints $165M biologics facilities; Tarveda to partner with Madrigal in $163M deal

9 years ago

Sarepta rockets up after FDA approves its controversial Duchenne drug

9 years ago

Scoop: J&J confirms that the FDA put AML drug on complete hold

9 years ago

Benitec’s abandoned one-dose hep C “cure” actually had two big problems

9 years ago

Lead vaccine from Vical and Astellas flops in a Phase II herpes study

9 years ago

Amgen’s expectations for romosozumab take a hit as Radius lines up its rival osteoporosis drug

9 years ago

Novartis shows a hole card in a high-stakes PhIII poker game for MS drugs

9 years ago

Amgen partners with Genenta, San Raffaele on an anti-tumor drug

9 years ago

Thumbs Up/Thumbs Down: The UN fumbles badly over access to drugs while developers think again about R&D strategies

9 years ago

Novo’s big reveal: GLP-1 drug semaglutide cuts cardio risks, but just may blind you

9 years ago

An acquisitive Celgene looks ready to pop a new multiple myeloma deal

9 years ago

Amgen, Novartis celebrate promising migraine data, but Teva and Alder are preparing to crash the party

9 years ago

The gamma delta T cell gambit inspires a small London biotech startup with big ideas

9 years ago

First page Previous page 1173 1174 117511761177 1178 1179 Next page Last page